Haleon

Haleon is a British multinational consumer healthcare company headquartered in Weybridge, England. It develops, markets, and sells over-the-counter medicines, oral-care products, vitamins and minerals, and other self-care products. Its portfolio includes internationally recognized brands such as Sensodyne, Panadol, Advil, and Centrum, giving the company a presence across pain relief, oral health, nutritional supplementation, and other consumer health categories. The company became an independent corporate group on 18 July 2022, when GSK separated its consumer healthcare operations through a corporate spin-off. Haleon's roots, however, extend to the 2019 combination of the consumer healthcare businesses of GSK and Pfizer. GSK held slightly more than two-thirds of the resulting joint venture, while Pfizer held the remaining interest. The combined business reported annual sales of approximately £10 billion across about 120 markets in 2020, creating one of the world's largest consumer healthcare operations. Haleon's business is organized around everyday health needs rather than prescription medicines. Oral health has been a particularly important area, accounting for 28.5% of revenue in 2021 according to the cited reference material. Sensodyne is associated with products for people with sensitive teeth, while the company's analgesic brands serve common pain and fever-relief needs. Its vitamin and mineral products, including Centrum, address supplementation and general wellness. The portfolio gives Haleon a mixture of pharmacy, grocery, mass retail, and e-commerce distribution. The spin-off was intended to allow GSK to concentrate more closely on biopharmaceuticals and vaccines while giving the consumer business independent strategic and financial focus. Haleon was listed in London and became a constituent of the FTSE 100; it also obtained a secondary listing in New York. Its ownership initially reflected the former GSK-Pfizer joint venture, but both founding shareholders subsequently reduced their stakes. GSK's holding fell to 7.4% in October 2023 and to 4.2% in January 2024, while Pfizer reduced its stake from 32% to 24% through a March 2024 public offering and sold its remaining holding in March 2025. After separation, Haleon also reshaped its portfolio. It sold the Lamisil antifungal brand to Karo Healthcare in 2023, the ChapStick lip-care brand to Yellow Wood Partners in 2024, and its non-U.S. nicotine-replacement-therapy business to Dr. Reddy's Laboratories later in 2024. The company announced manufacturing changes affecting Sensodyne toothpaste in the United Kingdom, including the planned closure of its Maidenhead factory and the transfer of manufacturing to Slovakia, alongside outsourcing of mouthwash production. These actions illustrate Haleon's effort to focus its operating model and concentrate resources on its core consumer-healthcare categories. Haleon is led by chairman Sir Dave Lewis and chief executive Brian McNamara. It operates as a standalone, internationally traded consumer-healthcare group rather than as a consumer division of GSK or Pfizer. Its positioning combines trusted mass-market brands, pharmacy credibility, scientific support, and broad everyday-use applications. The business remains active, although the supplied reference material does not provide a current revenue figure, detailed geographic breakdown, or a complete list of subsidiaries and brands.

Haleon's corporate history is rooted in the consolidation and subsequent separation of major pharmaceutical companies' consumer-healthcare activities. Before Haleon existed as a standalone company, GSK and Pfizer combined their consumer healthcare businesses in 2019. GSK owned slightly more than two-thirds of the resulting joint venture, while Pfizer owned the remainder. The combination brought together large portfolios of over-the-counter medicines, oral-care products, vitamins, and other self-care brands. By 2020, the combined operation generated approximately £10 billion in annual sales across around 120 markets. The consumer healthcare business was strategically distinct from GSK's prescription medicines, vaccines, and research operations. GSK announced plans to separate it in order to give the pharmaceutical group greater focus while allowing the consumer operation to pursue its own priorities. During the preparation for separation, Unilever reportedly offered approximately £50 billion for the business in 2022, but GSK rejected the proposal. Nestlé also examined a possible bid in cooperation with Reckitt, although no such transaction took place. Haleon was formally established on 18 July 2022 through the spin-off. The new company was headquartered in Weybridge, England, and became a separately listed business on the London Stock Exchange, where it joined the FTSE 100. It also received a secondary listing on the New York Stock Exchange. The initial shareholder structure reflected the preceding joint venture, with GSK and Pfizer retaining substantial interests after the separation. The portfolio spans several everyday health categories. Oral health was the largest reported area in the supplied historical reference, representing 28.5% of revenue in 2021. Sensodyne gave the business a strong position in toothpaste for sensitive teeth, while Panadol and Advil represented major analgesic franchises. Centrum provided a prominent vitamins-and-minerals platform. This combination of pharmacy products and mass-market consumer brands formed the basis of Haleon's positioning as a global consumer-healthcare specialist. Following the spin-off, the former parent shareholders progressively reduced their holdings. GSK lowered its stake to 7.4% in October 2023 and then to 4.2% in January 2024. Pfizer sold 630 million shares in March 2024, reducing its ownership from 32% to 24%, and sold its remaining interest in March 2025 for approximately £2.5 billion. These transactions completed the transition from a jointly owned GSK-Pfizer business to a broadly held public company. Haleon also reviewed the boundaries of its brand portfolio. In August 2023 it sold Lamisil to Karo Healthcare AB for £235 million. In February 2024 it sold ChapStick to Yellow Wood Partners for £401 million. In September 2024 it completed the sale of its non-U.S. nicotine-replacement-therapy business to Dr. Reddy's Laboratories for £458 million. These divestments reduced exposure to selected categories and allowed the company to concentrate on the consumer-healthcare activities it regarded as central to its standalone strategy. Operational changes accompanied the portfolio review. In April 2024 Haleon announced that it would close its Sensodyne toothpaste plant in Maidenhead and transfer production to Slovakia. It also planned to outsource mouthwash manufacturing to an unrelated producer. The measures indicate a move toward a more concentrated and potentially more flexible manufacturing network, although the supplied sources do not provide the final employment impact or detailed implementation timetable. Haleon is led by chairman Sir Dave Lewis and chief executive Brian McNamara. It remains an active international consumer-healthcare group whose principal commercial assets are brands used in routine self-care. The available reference material does not establish a complete current brand roster, detailed country-by-country operations, or later management changes, so those areas require further verification.

• 2025

  Pfizer completes its exit

  [1]Haleonen.wikipedia.org

  Pfizer sells its entire remaining Haleon stake for approximately £2.5 billion.

• 2024

  ChapStick is divested

  [1]Haleonen.wikipedia.org

  Haleon sells ChapStick to Yellow Wood Partners for £401 million.

• 2024

  Manufacturing network is revised

  [1]Haleonen.wikipedia.org

  Haleon announces the planned closure of its Maidenhead Sensodyne factory, transfer of production to Slovakia, and outsourcing of mouthwash manufacturing.

• 2024

  Non-U.S. nicotine-replacement business is sold

  [1]Haleonen.wikipedia.org

  Haleon completes the sale of its non-U.S. nicotine-replacement-therapy business to Dr. Reddy's Laboratories for £458 million.

• 2023

  Lamisil is divested

  [1]Haleonen.wikipedia.org

  Haleon sells the Lamisil antifungal brand to Karo Healthcare AB for £235 million.

• 2022

  Haleon is established as an independent company

  [1]Haleonen.wikipedia.org

  Haleon is created on 18 July through the spin-off of GSK's consumer healthcare business.

• 2022

  Haleon becomes publicly listed

  [1]Haleonen.wikipedia.org

  The company is listed on the London Stock Exchange, joins the FTSE 100, and receives a secondary New York Stock Exchange listing.

• 2020

  Combined consumer healthcare business reports approximately £10 billion in sales

  [1]Haleonen.wikipedia.org

  The combined GSK-Pfizer consumer healthcare operation records annual sales of about £10 billion across approximately 120 markets.

• 2019

  GSK and Pfizer combine consumer healthcare businesses

  [1]Haleonen.wikipedia.org

  GSK and Pfizer merge their consumer healthcare operations into a joint venture, with GSK holding slightly more than two-thirds and Pfizer holding the balance.

A global consumer-healthcare company focused on trusted, science-backed brands for everyday health needs, with particular strength in oral care, pain relief, and vitamins and minerals.

• Oral care

  Sensodyne

  Sensodyne is Haleon's specialist oral-care brand for consumers concerned about sensitive teeth. Its portfolio is centered on toothpaste and related oral-hygiene products. The brand is one of Haleon's most prominent global franchises and was associated with the Maidenhead manufacturing facility whose planned closure and production transfer were announced in 2024.

• Pain relief

  Panadol

  Panadol is a major Haleon analgesic brand used for common pain and fever-relief needs. It is part of the company's over-the-counter medicines portfolio and contributes to Haleon's international presence in self-care products sold through pharmacies, retailers, and other consumer channels.

• Pain relief

  Advil

  Advil is Haleon's pain-relief brand and one of the company's named flagship offerings. It sits within the over-the-counter medicines business and serves everyday analgesic needs, particularly in markets where the Advil brand is distributed.

• Vitamins and minerals

  Centrum

  Centrum is Haleon's leading vitamins-and-minerals brand. It addresses supplementation and general wellness through consumer products intended for different nutritional and life-stage needs. The brand broadens Haleon's business beyond medicines and oral care into preventive and everyday health.

• Antifungal treatment

  Lamisil

  Lamisil was Haleon's antifungal brand before its sale to Karo Healthcare AB in 2023. The divestment removed the brand from Haleon's portfolio as the company refined its standalone consumer-healthcare scope.

• Lip care

  ChapStick

  ChapStick was Haleon's lip-care brand until it was sold to Yellow Wood Partners in 2024. Its divestment formed part of Haleon's post-spin-off portfolio reshaping.

• 2024

  Sell ChapStick to Yellow Wood PartnersM&A

  Background

  Haleon continued to refine the portfolio inherited from the GSK-Pfizer consumer healthcare combination.

  Action taken

  Haleon sold the ChapStick lip-care brand to Yellow Wood Partners for £401 million.

  Aftermath

  ChapStick was divested from Haleon.

  Sale consideration. £401 million (February 2024)

  Source

• 2024

  Restructure Sensodyne and mouthwash manufacturingStrategy

  Background

  Haleon announced changes to its oral-care manufacturing footprint as part of its operating-model review.

  Action taken

  The company announced the closure of its Maidenhead Sensodyne toothpaste factory, transfer of production to Slovakia, and outsourcing of mouthwash manufacturing.

  Aftermath

  The announced changes were intended to alter Haleon's manufacturing network, although the supplied material does not specify the final employment or cost impact.

  Source

• 2024

  Sell non-U.S. nicotine-replacement business to Dr. Reddy'sM&A

  Background

  Haleon continued to narrow its portfolio geographically and by category after the corporate separation.

  Action taken

  Haleon completed the sale of its non-U.S. nicotine-replacement-therapy business to Dr. Reddy's Laboratories.

  Aftermath

  The non-U.S. nicotine-replacement business transferred to Dr. Reddy's Laboratories.

  Sale consideration. £458 million (September 2024)

  Source

• 2023

  Sell Lamisil to Karo HealthcareM&A

  Background

  Haleon reviewed its portfolio after becoming an independent company.

  Action taken

  The company sold Lamisil to Karo Healthcare AB for £235 million.

  Aftermath

  Lamisil left Haleon's brand portfolio.

  Sale consideration. £235 million (August 2023)

  Source

• 2022

  Proceed with the Haleon spin-offM&A

  Background

  GSK sought to give greater strategic focus to its pharmaceutical and vaccine activities while separating its large consumer healthcare operation into an independent company.

  Action taken

  GSK established Haleon through the separation of the consumer healthcare business on 18 July 2022.

  Aftermath

  Haleon became a separately listed international consumer-healthcare group, while GSK and Pfizer initially retained substantial ownership interests.

  Source

• 2022

  Reject Unilever's reported acquisition proposalM&A

  Background

  Unilever reportedly offered approximately £50 billion for the consumer healthcare business during the period surrounding the planned separation.

  Action taken

  GSK rejected the reported offer and proceeded with the spin-off route.

  Aftermath

  The consumer healthcare business became Haleon rather than being acquired by Unilever.

  Reported acquisition proposal. £50 billion offer rejected (2022)

  Source

1. 1Haleonen.wikipedia.org